The fastest way to change yourself is to hang out with people who are already the way you want to be.
Every weekday, we hand you a mad startup idea - as fresh as Anthropic dropping Opus 4.8 🆕! What you do with it is up to you.
✅ 4 sections ⏱️ 4 minutes 🚫 No fluff.
💡 Mad Idea • 📈 Mad Trends • 🛠 Mad Hack • 📰 Mad News
MEDIMITRA 💊
The Challenge: The ₹85,000 Cr OOP Drug Spend 💸
Indians pay ₹85,000 crore out-of-pocket every year for prescription drugs. 60% of that goes to branded generics — the same molecule as a cheaper generic, sold at 6-12x the price.
Take atorvastatin (cholesterol drug, 7 crore Indians take it daily). Generic price: ₹2/tablet. Sun Pharma's Atorva: ₹14/tablet. Same molecule. Same effect. Same factory sometimes. 7x markup is just brand premium + doctor commission.
PMBJP (PM's Janaushadhi) tried — 14,000 government stores. But: stockouts, limited SKUs, no doorstep delivery, no doctor consultation. 1mg and PharmEasy went the opposite way — premium branded model. The middle class still bleeds ₹50,000+ crore in unnecessary drug markups annually. 🤡
The Product: MediMitra — Generic-First Pharmacy with Doctor Layer 🛠️
A 1mg-clone optimized only for generics + doctor consultation, not branded discount marketing.
💊 Generic Substitution Engine: Upload prescription. AI extracts molecule names. Suggests verified generic equivalent. Shows price comparison: branded vs generic. Patient saves 60-80% per purchase.
👨⚕️ Doctor-Verified Switch: Every generic swap is co-signed by a MediMitra panel doctor (free 5-min telecon). Patient is comfortable. Doctor earns ₹50 per consult. Pharmacy delivers in 24 hours.
🤝 Chronic Subscription: Diabetes, BP, cholesterol — 70% of OOP spend is chronic medication. Auto-deliver monthly via subscription. Skip the trip. Save 65% vs branded equivalent.
🏥 Aushadhi-Integration: Partner with PMBJP stores for last-mile. They get demand. We get scale. India's first government-startup pharmacy hybrid.
Business Model🤑🤑:
Markup (12-18%) on generic medicines: Far thinner than branded markup, volume-driven.
Subscription (₹99/month): Chronic patients pay for auto-refill + doctor access.
Doctor consultation fee (₹50 per switch): Doctors earn passive income for medical reviews.
Exit Strategy: Become India's largest generic pharmacy network. Then expand to OTC, diagnostics, home health. Acquisition target: Tata 1mg, PharmEasy, or Reliance Health at a 6–10x revenue multiple. Or — and this is the bigger bet — pitch to NPPA (National Pharma Pricing Authority) to become the government's generic-first procurement partner. ₹85,000 Cr of OOP drug spending is begging for disruption.
India's biotech & gene therapy window is opening 🧬
₹500 crore cancer treatment — now possible at ₹60,000 in India. Cell + gene therapy is having its UPI moment.
The Shift: From "generic pharma manufacturing capital of the world" to "low-cost biotech innovator of the world." Indian biotech startups are designing CAR-T, mRNA, gene therapies that cost 5-10x less than US/Europe equivalents.
The Trend: Cellogen Therapeutics, Immuneel, Ramraj — Indian biotechs targeting cancers, sickle cell, thalassemia at fraction of global pricing. Manufacturing in Noida, Bengaluru. CMC Vellore running Phase-1 trials. The next decade's pharma exports.
The Drivers:
Cost Advantage: $500K → $60K treatment cost compression for CAR-T (10x cheaper than Novartis/Gilead).
Startup Count: 11,000+ Indian biotech startups operating in 2026.
Market Potential:$50B projected Indian biotech market by 2030.
❝🔥Is next unicorn coming from this space ? Unlike SaaS or D2C — biotech requires patient capital, deep science, regulatory expertise. Most VCs aren't built for 8-year timelines. The fund or founder who masters Indian biotech in 2026-30 builds the next Sun Pharma — at $10B+ valuation, with global cancer-treatment moat.
Cred's "bored CFO" weekly email. 📧
Kunal Shah's email open rates in 2018 were 73%. Industry average: 12%. The trick wasn't the offer.
The Backstory: In 2018, Cred had 3 lakh users. Weekly email engagement was the only retention metric that mattered. Most fintech newsletters were dry — "rewards earned this week," "your credit score is XX." Generic. Boring. Unopened.
The Move: Kunal personally wrote weekly emails in a voice he called "the bored CFO." Each email opened with a confession, observation, or off-topic rant from a fictional senior finance professional. "I noticed something this week while watching my CFO complain about expense reports..." Then he'd weave in the Cred feature/reward — only at the end. Often ironically. Often making fun of fintech itself.
The Compound: Open rates went from 12% to 73%. Forward rates went to 8%. Cred's email list became the highest-engagement marketing channel in Indian fintech. Founders asked: "Can I copy your email style?" Kunal: "Sure, but you'd have to copy my brain too."
The Payoff: Cred is $6.4B valued, ~2 crore active users. The "bored CFO" voice became Cred's brand. Half of their early growth came from email — not ads, not influencers, not push notifications.
🎯 The Builder Lesson: Brand voice isn't a "tone of voice document." It's a character the founder writes from. If your emails sound like every other startup's emails, you've lost before the customer opens it. Voice > Offer.
🤖 Anthropic drops Claude Opus 4.8 — Coding/agentic powerhouse for massive scale.
💳 Paytm launches 'Pocket Money' UPI feature for teens with parental controls — Built on UPI Circle. Next 8 crore Indians enter digital payments without a bank account.
📈 Bharti Airtel overtakes HDFC to become 2nd-most-valuable listed Indian co — ₹11.78 lakh Cr m-cap. 270% returns in 5 years vs HDFC Bank's 49%. India's market hierarchy is changing.
🌾 ONO raises $1.2M pre-Series A from Aeravti Ventures for agri-finance — AI-led platform for post-harvest supply chain credit. Tier-3 agri-SME credit finally gets data-led underwriting.